Cargando…
A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
Talimogene laherparepvec (T‐VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open‐label, dose de‐escalation study evaluated the safety and efficacy of T‐VEC in Japanese patients with unresectable stage IIIB–IV melanoma. Eligibl...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357627/ https://www.ncbi.nlm.nih.gov/pubmed/35656636 http://dx.doi.org/10.1111/cas.15450 |
_version_ | 1784763751497465856 |
---|---|
author | Yamazaki, Naoya Isei, Taiki Kiyohara, Yoshio Koga, Hiroshi Kojima, Takashi Takenouchi, Tatsuya Yokota, Kenji Namikawa, Kenjiro Yi, Min Keegan, Alissa Fukushima, Satoshi |
author_facet | Yamazaki, Naoya Isei, Taiki Kiyohara, Yoshio Koga, Hiroshi Kojima, Takashi Takenouchi, Tatsuya Yokota, Kenji Namikawa, Kenjiro Yi, Min Keegan, Alissa Fukushima, Satoshi |
author_sort | Yamazaki, Naoya |
collection | PubMed |
description | Talimogene laherparepvec (T‐VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open‐label, dose de‐escalation study evaluated the safety and efficacy of T‐VEC in Japanese patients with unresectable stage IIIB–IV melanoma. Eligible adult patients had histologically confirmed stage IIIB–IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had ≥1 injectable lesion, serum lactate dehydrogenase ≤1.5x upper limit of normal, ECOG performance status of 0 or 1, and adequate hematologic, hepatic, and renal function. T‐VEC was injected intralesionally (first dose, ≤4.0 ml of 10(6) PFU/ml; after 3 weeks and then every 2 weeks thereafter, ≤4.0 ml of 10(8) PFU/ml). Primary endpoints were dose‐limiting toxicities (DLTs) and durable response rate (DRR). Of 18 enrolled patients (72.2% female), 16 had received ≥1 prior line of therapy. Ten patients discontinued T‐VEC due to disease progression. Median (range) follow‐up was 20.0 (4–37) months. No DLTs were observed; 17 (94.4%) patients had treatment‐emergent adverse events (AEs). Fourteen (77.8%) patients had treatment‐related AEs; the most frequent were pyrexia (44.4%), malaise (16.7%), chills, decreased appetite, pruritus, and skin ulcer (11.1% each). The primary efficacy endpoint was met: 2 (11.1%) patients had a durable partial response ≥6 months. The DRR was consistent with that observed in a phase III trial of T‐VEC in non‐Asian patients. The safety profile was consistent with the patients' underlying disease and the known safety profile of T‐VEC. |
format | Online Article Text |
id | pubmed-9357627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93576272022-08-09 A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma Yamazaki, Naoya Isei, Taiki Kiyohara, Yoshio Koga, Hiroshi Kojima, Takashi Takenouchi, Tatsuya Yokota, Kenji Namikawa, Kenjiro Yi, Min Keegan, Alissa Fukushima, Satoshi Cancer Sci ORIGINAL ARTICLES Talimogene laherparepvec (T‐VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open‐label, dose de‐escalation study evaluated the safety and efficacy of T‐VEC in Japanese patients with unresectable stage IIIB–IV melanoma. Eligible adult patients had histologically confirmed stage IIIB–IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had ≥1 injectable lesion, serum lactate dehydrogenase ≤1.5x upper limit of normal, ECOG performance status of 0 or 1, and adequate hematologic, hepatic, and renal function. T‐VEC was injected intralesionally (first dose, ≤4.0 ml of 10(6) PFU/ml; after 3 weeks and then every 2 weeks thereafter, ≤4.0 ml of 10(8) PFU/ml). Primary endpoints were dose‐limiting toxicities (DLTs) and durable response rate (DRR). Of 18 enrolled patients (72.2% female), 16 had received ≥1 prior line of therapy. Ten patients discontinued T‐VEC due to disease progression. Median (range) follow‐up was 20.0 (4–37) months. No DLTs were observed; 17 (94.4%) patients had treatment‐emergent adverse events (AEs). Fourteen (77.8%) patients had treatment‐related AEs; the most frequent were pyrexia (44.4%), malaise (16.7%), chills, decreased appetite, pruritus, and skin ulcer (11.1% each). The primary efficacy endpoint was met: 2 (11.1%) patients had a durable partial response ≥6 months. The DRR was consistent with that observed in a phase III trial of T‐VEC in non‐Asian patients. The safety profile was consistent with the patients' underlying disease and the known safety profile of T‐VEC. John Wiley and Sons Inc. 2022-06-30 2022-08 /pmc/articles/PMC9357627/ /pubmed/35656636 http://dx.doi.org/10.1111/cas.15450 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ORIGINAL ARTICLES Yamazaki, Naoya Isei, Taiki Kiyohara, Yoshio Koga, Hiroshi Kojima, Takashi Takenouchi, Tatsuya Yokota, Kenji Namikawa, Kenjiro Yi, Min Keegan, Alissa Fukushima, Satoshi A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma |
title | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma |
title_full | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma |
title_fullStr | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma |
title_full_unstemmed | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma |
title_short | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma |
title_sort | phase i study of the safety and efficacy of talimogene laherparepvec in japanese patients with advanced melanoma |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357627/ https://www.ncbi.nlm.nih.gov/pubmed/35656636 http://dx.doi.org/10.1111/cas.15450 |
work_keys_str_mv | AT yamazakinaoya aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT iseitaiki aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT kiyoharayoshio aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT kogahiroshi aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT kojimatakashi aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT takenouchitatsuya aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT yokotakenji aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT namikawakenjiro aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT yimin aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT keeganalissa aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT fukushimasatoshi aphaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT yamazakinaoya phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT iseitaiki phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT kiyoharayoshio phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT kogahiroshi phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT kojimatakashi phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT takenouchitatsuya phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT yokotakenji phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT namikawakenjiro phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT yimin phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT keeganalissa phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma AT fukushimasatoshi phaseistudyofthesafetyandefficacyoftalimogenelaherparepvecinjapanesepatientswithadvancedmelanoma |